The Journal of pediatrics
-
The Journal of pediatrics · Sep 2011
Randomized Controlled TrialInhaled beta-2 agonist salbutamol for the treatment of transient tachypnea of the newborn.
To evaluate the efficacy of inhaled salbutamol, a beta-2 adrenergic agonist, for the treatment of transient tachypnea of the newborn (TTN) and to determine whether inhaled salbutamol is safe in newborn infants. ⋯ Inhaled salbutamol treatment was effective with respect to both clinical and laboratory findings of TTN and without adverse events.